Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1

Pharmacogenetics

Volumn 13, Issue 5, 2003, Pages 297-301

  Osato, Douglas H ^a   Huang, Conrad C ^a   Kawamoto, Michiko ^a   Johns, Susan J ^a   Stryke, Doug ^a   Wang, Joanne ^b   Ferrin, Thomas E ^a   Herskowitz, Ira ^a,c   Giacomini, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Nucleoside; Nucleoside analogs; Polymorphisms; Transporter

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARRIER PROTEIN; CYTARABINE; DILAZEP; DIPYRIDAMOLE; FLUOROURIDINE; GEMCITABINE; INOSINE; NUCLEOSIDE ANALOG; PROTEIN ENT1; RIBAVIRIN; TUBERCIDIN; UNCLASSIFIED DRUG; URIDINE;

ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG TRANSPORT; ETHNIC DIFFERENCE; GENETIC CODE; GENETIC VARIABILITY; HAPLOTYPE; IC 50; INHIBITION KINETICS; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TRANSPORT KINETICS;

AMINO ACID SEQUENCE; CLONING, MOLECULAR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NUCLEOSIDES; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; SEQUENCE ALIGNMENT; VARIATION (GENETICS);

SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 0037565518     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200305000-00010     Document Type: Article

References (12)

1. Plagemann PGW, Wohlhueter RM, Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta 1988; 947: 405-443.
2. Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol 2001; 18:53-63.
3. Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001; 60:8-18.
4. Bodenheimer Jr HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic Hepatitis C: a multicenter trial. Hepatology 1997; 26:473-477.
5. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002; 12:395-405.
6. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor T, de la Cruz M, et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci 2003; in press.
7. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
8. Baudin A, Ozier-Kalogeropoulos O, Denouel A, Lacroute F, Cullin C. A simple and efficient method for direct gene deletion in Saccharomyces cerevisiae. Nucleic Acids Res 1993; 21:3329-3330.
9. Ito H, Fukada Y, Murata K, Kimura A. Transformation of intact yeast cells treated with alkali cations. J Bacteriol 1983; 153:163-168.
10. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci 2003; in press.
11. Grantham R. Amino acid difference formula to help explain protein evolution. Science 1974; 185:862-864.
12. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 1989; 123:585-595.